Prospects and Challenges of Reprogrammed Cells in Hematology and Oncology

REFERENCES

• Reeves RH, Irving NG, Moran TH, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11:177–184, doi:10.1038/ng1095-177.
   PubMed Web of Science ®Google Scholar
• Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–1147.
   PubMed Web of Science ®Google Scholar
• Islam MS, Ni Z, Kaufman DS. Use of human embryonic stem cells to understand hematopoiesis and hematopoietic stem cell niche. Curr Stem Cell Res Ther. 2010;5:245–250.
   PubMed Web of Science ®Google Scholar
• Itskovitz-Eldor J, Schuldiner M, Karsenti D, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med. 2000;6:88–95.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872, doi:10.1016/j.cell.2007.11.019.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676, doi:10.1016/j.cell.2006.07.024.
   PubMed Web of Science ®Google Scholar
• Wu GM, Liu N, Rittelmeyer I, et al. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol. 2011;9:e1001099, doi:10.1371/journal.pbio.1001099.
   PubMed Web of Science ®Google Scholar
• Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation. Nature. 2009;461:86–90, doi:10.1038/Nature08267.
   PubMed Web of Science ®Google Scholar
• Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1269–1275, doi:10.1038/nbt.1502.
   PubMed Web of Science ®Google Scholar
• Li W, Zhou H, Abujarour R, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells. 2009;27:2992–3000, doi:10.1002/stem.240.
   PubMed Web of Science ®Google Scholar
• Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920, doi:10.1126/science.1151526.
   PubMed Web of Science ®Google Scholar
• Hester ME, Song SW, Miranda CJ, et al. Two factor reprogramming of human neural stem cells into pluripotency. PLoS ONE. 2009;4:e7044, doi:10.1371/journal.pone.0007044.
   PubMed Web of Science ®Google Scholar
• Theunissen TW, van Oosten AL, Castelo-Branco G, et al. Nanog overcomes reprogramming barriers and induces pluripotency in minimal conditions. Curr Biol. 2011;21:65–71, doi:10.1016/j.cub.2010.11.074.
   PubMed Web of Science ®Google Scholar
• Kim JB, Greber B, Arauzo-Bravo MJ, et al. Direct reprogramming of human neural stem cells by OCT4. Nature. 2009;461:649–653, doi:10.1038/nature08436.
   PubMed Web of Science ®Google Scholar
• Thomson M, Liu SJ, Zou L-N, et al. Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell. 2011;145:875–889, doi:10.1016/j.cell.2011.05.017.
   PubMed Web of Science ®Google Scholar
• Rodda DJ, Chew JL, Lim LH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem. 2005;280:24731–24737, doi:10.1074/jbc.M502573200.
   PubMed Web of Science ®Google Scholar
• Pan GJ, Chang ZY, Scholer HR, Pei D. Stem cell pluripotency and transcription factor Oct4. Cell Res. 2002;12:321–329, doi:10.1038/sj.cr.7290134.
   PubMed Web of Science ®Google Scholar
• Yamanaka S, Li J, Kania G, et al. Pluripotency of embryonic stem cells. Cell Tissue Res. 2008;331:5–22, doi:10.1007/s00441-007-0520-5.
   PubMed Web of Science ®Google Scholar
• Chew JL, Loh YH, Zhang W, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25:6031–6046, doi:10.1128/MCB.25.14.6031-6046.2005.
   PubMed Web of Science ®Google Scholar
• zur Nieden NI, Cormier JT, Rancourt DE, Kallos MS. Embryonic stem cells remain highly pluripotent following long term expansion as aggregates in suspension bioreactors. J Biotechnol. 2007;129:421–432, doi:10.1016/j.jbiotec.2007.01.006.
   PubMed Web of Science ®Google Scholar
• Carey BW, Markoulaki S, Hanna J, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci USA. 2009;106:157–162, doi:10.1073/pnas.0811426106.
   PubMed Web of Science ®Google Scholar
• Chang CW, Lai YS, Pawlik KM, et al. Polycistronic lentiviral vector for “hit and run” reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells. 2009;27:1042–1049, doi:10.1002/stem.39.
   PubMed Web of Science ®Google Scholar
• Papapetrou EP, Sadelain M. Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nat Protoc. 2011;6:1251–1273, doi:10.1038/nprot.2011.374.
   PubMed Web of Science ®Google Scholar
• Si-Tayeb K, Noto FK, Sepac A, et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol. 2010;10:81, doi:10.1186/1471-213X-10-81.
   PubMed Web of Science ®Google Scholar
• Warlich E, Kuehle J, Cantz T, et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther: J Am Soc Gene Ther. 2011;19:782–789, doi:10.1038/mt.2010.314.
   PubMed Web of Science ®Google Scholar
• Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods. 2009;6:363–369, doi:10.1038/nmeth.1323.
   PubMed Web of Science ®Google Scholar
• Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 2011;8:376–388, doi:10.1016/j.stem.2011.03.001.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–476, doi:10.1016/j.stem.2009.05.005.
   PubMed Web of Science ®Google Scholar
• Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4:381–384, doi:10.1016/j.stem.2009.04.005.
   PubMed Web of Science ®Google Scholar
• Plews JR, Li J, Jones M, et al. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS ONE. 2010;5:e14397, doi:10.1371/journal.pone.0014397.
   PubMed Web of Science ®Google Scholar
• Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7:618–630, doi:10.1016/j.stem.2010.08.012.
   PubMed Web of Science ®Google Scholar
• Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun. 2010;394:189–193, doi:10.1016/j.bbrc.2010.02.150.
   PubMed Web of Science ®Google Scholar
• Voelkel C, Galla M, Maetzig T, et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci USA. 2010;107:7805–7810, doi:10.1073/pnas.0914517107.
   PubMed Web of Science ®Google Scholar
• Novak A, Shtrichman R, Germanguz I, et al. Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles, using a single excisable lentivirus. Cell Reprog. 2010;12:665–678, doi:10.1089/cell.2010.0027.
   PubMed Web of Science ®Google Scholar
• Fang Y, Orner BP. Induction of pluripotency in fibroblasts through the expression of only four nuclear proteins. ACS Chem Biol. 2006;1:557–558, doi:10.1021/cb600402w.
   PubMed Web of Science ®Google Scholar
• Picanco-Castro V, Russo-Carbolante E, Reis LC, et al. Pluripotent reprogramming of fibroblasts by lentiviral mediated insertion of SOX2, C-MYC, and TCL-1A. Stem Cells Dev. 2011;20:169–180, doi:10.1089/scd.2009.0424.
   PubMed Web of Science ®Google Scholar
• Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458:766–770, doi:10.1038/nature07863.
   PubMed Web of Science ®Google Scholar
• Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011;117:e109–e119, doi:10.1182/blood-2010-07-298331.
   PubMed Web of Science ®Google Scholar
• Kunisato A, Wakatsuki M, Kodama Y, et al. Generation of induced pluripotent stem cells by efficient reprogramming of adult bone marrow cells. Stem Cells Dev. 2010;19:229–238, doi:10.1089/scd.2009.0149.
   PubMed Web of Science ®Google Scholar
• Meng X, Neises A, Su RJ, et al. Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther: J Am Soc Gene Ther. 2012;20:408–416, doi:10.1038/mt.2011.258.
   PubMed Web of Science ®Google Scholar
• Ye Z, Zhan H, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood. 2009;114:5473–5480, doi:10.1182/blood-2009-04-217406.
   PubMed Web of Science ®Google Scholar
• Brown ME, Rondon E, Rajesh D, et al. Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS ONE. 2010;5:e11373, doi:10.1371/journal.pone. 0011373.
   PubMed Web of Science ®Google Scholar
• Haase A, Olmer R, Schwanke K, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell. 2009;5:434–441, doi:10.1016/j.stem.2009.08.021.
   PubMed Web of Science ®Google Scholar
• Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell. 2009;5:353–357, doi:10.1016/j.stem.2009.09.008.
   PubMed Web of Science ®Google Scholar
• Loh YH, Agarwal S, Park IH, et al. Generation of induced pluripotent stem cells from human blood. Blood. 2009;113:5476–5479, doi:10.1182/blood-2009-02-204800.
   PubMed Web of Science ®Google Scholar
• Seki T, Yuasa S, Fukuda K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc. 2012;7:718–728, doi:10.1038/nprot.2012.015.
   PubMed Web of Science ®Google Scholar
• Staerk J, Dawlaty MM, Gao Q, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7:20–24, doi:10.1016/j.stem.2010.06.002.
   PubMed Web of Science ®Google Scholar
• Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell. 2009;5:584–595, doi:10.1016/j.stem.2009.11.009.
   PubMed Web of Science ®Google Scholar
• Gross B, Sgodda M, Rasche M, et al. Improved generation of patient-specific induced pluripotent stem cells using a chemically defined and Matrigel-based approach. Curr Mol Med; in press.
   Web of Science ®Google Scholar
• Koche RP, Smith ZD, Adli M, et al. Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell. 2011;8:96–105, doi:10.1016/j.stem.2010.12.001.
   PubMed Web of Science ®Google Scholar
• Silva J, Barrandon O, Nichols J, et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 2008;6:e253, doi:10.1371/journal.pbio.0060253.
   PubMed Web of Science ®Google Scholar
• Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature. 2008;454:49–55, doi:10.1038/nature07056.
   PubMed Web of Science ®Google Scholar
• Kretsovali A, Hadjimichael C, Charmpilas N. Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int. 2012;2012:184154, doi:10.1155/2012/ 184154.
   PubMed Web of Science ®Google Scholar
• Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26:795–797, doi:10.1038/nbt1418.
   PubMed Web of Science ®Google Scholar
• Li W, Wei W, Zhu S, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell. 2009;4:16–19, doi:10.1016/j.stem.2008.11.014.
   PubMed Web of Science ®Google Scholar
• Lin T, Ambasudhan R, Yuan X, et al. A chemical platform for improved induction of human iPSCs. Nat Methods. 2009;6:805–808, doi:10.1038/nmeth.1393.
   PubMed Web of Science ®Google Scholar
• Ichida JK, Blanchard J, Lam K, et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell. 2009;5:491–503, doi:10.1016/j.stem.2009.09.012.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007;25:681–686, doi:10.1038/nbt1310.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu X, Hahm HS, et al. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc Natl Acad Sci USA. 2010;107:8129–8134, doi:10.1073/pnas.1002024107.
   PubMed Web of Science ®Google Scholar
• Esteban MA, Wang T, Qin B, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2010;6:71–79, doi:10.1016/j.stem.2009.12.001.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhao Y, Deng H. Powering reprogramming with vitamin C. Cell Stem Cell. 2010;6:1–2, doi:10.1016/j.stem.2009.12.012.
   PubMed Web of Science ®Google Scholar
• Wang T, Chen K, Zeng X, et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 2011;9:575–587, doi:10.1016/j.stem.2011.10.005.
   PubMed Web of Science ®Google Scholar
• Greenlee AR, Kronenwetter-Koepel TA, Kaiser SJ, et al. Combined effects of Matrigel and growth factors on maintaining undifferentiated murine embryonic stem cells for embryotoxicity testing. Toxicol In Vitro. 2004;18:543–553, doi:10.1016/j.tiv.2004.01.013.
   PubMed Web of Science ®Google Scholar
• Greenlee AR, Kronenwetter-Koepel TA, Kaiser SJ, Liu K. Comparison of Matrigel and gelatin substrata for feeder-free culture of undifferentiated mouse embryonic stem cells for toxicity testing. Toxicol In Vitro. 2005;19:389–397, doi:10.1016/j.tiv.2004.11.002.
   PubMed Web of Science ®Google Scholar
• Zhou YP, Rochat A, Hatzfeld A, et al. bFGF-stimulated MEF-conditioned medium is capable of maintaining human embryonic stem cells. Fen Zi Xi Bao Sheng Wu Xue Bao. 2009;42:193–199.
   PubMedGoogle Scholar
• Heydarkhan-Hagvall S, Gluck JM, Delman C, et al. The effect of vitronectin on the differentiation of embryonic stem cells in a 3D culture system. Biomaterials. 2012;33:2032–2040, doi:10.1016/j.biomaterials.2011.11.065.
   PubMed Web of Science ®Google Scholar
• Li J, Bardy J, Yap LY, et al. Impact of vitronectin concentration and surface properties on the stable propagation of human embryonic stem cells. Biointerphases. 2010;5:FA132–FA142, doi:10.1116/1.3525804.
   PubMed Web of Science ®Google Scholar
• Li Z, Leung M, Hopper R, et al. Feeder-free self-renewal of human embryonic stem cells in 3D porous natural polymer scaffolds. Biomaterials. 2010;31:404–412, doi:10.1016/ j.biomaterials.2009.09.070.
   PubMed Web of Science ®Google Scholar
• Mahlstedt MM, Anderson D, Sharp JS, et al. Maintenance of pluripotency in human embryonic stem cells cultured on a synthetic substrate in conditioned medium. Biotechnol Bioeng. 2010;105:130–140, doi:10.1002/bit.22520.
   PubMed Web of Science ®Google Scholar
• Ludwig TE, Bergendahl V, Levenstein ME, et al. Feeder-independent culture of human embryonic stem cells. Nat Methods. 2006;3:637–646, doi:10.1038/nmeth902.
   PubMed Web of Science ®Google Scholar
• Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol. 2006;24:185–187, doi:10.1038/nbt1177.
   PubMed Web of Science ®Google Scholar
• Olmer R, Haase A, Merkert S, et al. Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. Stem Cell Res. 2010;5:51–64, doi:10.1016/j.scr.2010.03.005.
   PubMed Web of Science ®Google Scholar
• Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell. 2011;8:106–118, doi:10.1016/j.stem.2010.12.003.
   PubMed Web of Science ®Google Scholar
• Bock C, Kiskinis E, Verstappen G, et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell. 2011;144:439–452, doi:10.1016/j.cell.2010.12.032.
   PubMed Web of Science ®Google Scholar
• Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009;5:111–123, doi:10.1016/j.stem.2009.06.008.
   PubMed Web of Science ®Google Scholar
• Chin MH, Pellegrini M, Plath K, Lowry WE. Molecular analyses of human induced pluripotent stem cells and embryonic stem cells. Cell Stem Cell. 2010;7:263–269, doi:10.1016/j.stem.2010. 06.019.
   PubMed Web of Science ®Google Scholar
• Narva E, Autio R, Rahkonen N, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol. 2010;28:371–377, doi:10.1038/nbt.1615.
   PubMed Web of Science ®Google Scholar
• Spits C, Mateizel I, Geens M, et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol. 2008;26:1361–1363, doi:10.1038/nbt.1510.
   PubMed Web of Science ®Google Scholar
• Baker DE, Harrison NJ, Maltby E, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol. 2007;25:207–215, doi:10.1038/nbt1285.
   PubMed Web of Science ®Google Scholar
• Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol. 2004;22:53–54, doi:10.1038/nbt922.
   PubMed Web of Science ®Google Scholar
• Mitalipova MM, Rao RR, Hoyer DM, et al. Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol. 2005;23:19–20, doi:10.1038/nbt0105-19.
   PubMed Web of Science ®Google Scholar
• Martins-Taylor K, Nisler BS, Taapken SM, et al. Recurrent copy number variations in human induced pluripotent stem cells. Nat Biotechnol. 2011;29:488–491, doi:10.1038/nbt.1890.
   PubMed Web of Science ®Google Scholar
• Newman AM, Cooper JB. Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell. 2010;7:258–262, doi:10.1016/j.stem.2010.06.016.
   PubMed Web of Science ®Google Scholar
• Dommergues M, Aubeny E, Dumez Y, et al. Hematopoiesis in the human yolk sac: quantitation of erythroid and granulopoietic progenitors between 3.5 and 8 weeks of development. Bone Marrow Transpl. 1992;9(Suppl. 1):23–27.
   PubMedGoogle Scholar
• Durand C, Dzierzak E. Embryonic beginnings of adult hematopoietic stem cells. Haematologica. 2005;90:100–108.
   PubMed Web of Science ®Google Scholar
• Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell. 1996;86:897–906.
   PubMed Web of Science ®Google Scholar
• Yahata T, Muguruma Y, Yumino S, et al. Quiescent human hematopoietic stem cells in the bone marrow niches organize the hierarchical structure of hematopoiesis. Stem Cells. 2008;26:3228–3236, doi:10.1634/stemcells.2008-0552.
   PubMed Web of Science ®Google Scholar
• Choi KD, Vodyanik MA, Slukvin II. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived line-CD34+CD43+CD45+ progenitors. J Clin Invest. 2009;119:2818–2829, doi:10.1172/JCI38591.
   PubMed Web of Science ®Google Scholar
• Choi KD, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. 2009;27:559–567, doi:10.1634/stemcells.2008-0922.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim BS, Ryu SW, et al. Hematopoietic differentiation of embryoid bodies derived from the human embryonic stem cell line SNUhES3 in co-culture with human bone marrow stromal cells. Yonsei Med J. 2005;46:693–699.
   PubMed Web of Science ®Google Scholar
• Ledran MH, Krassowska A, Armstrong L, et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell. 2008;3:85–98, doi:10.1016/j.stem.2008.06.001.
   PubMed Web of Science ®Google Scholar
• Ng ES, Davis RP, Hatzistavrou T, et al. Directed differentiation of human embryonic stem cells as spin embryoid bodies and a description of the hematopoietic blast colony forming assay. Curr Protoc Stem Cell Biol. 2008;Chapter 1:Unit 1D.3, doi:10.1002/9780470151808.sc01d03s4.
   PubMedGoogle Scholar
• Niwa A, Heike T, Umeda K, et al. A novel serum-free monolayer culture for orderly hematopoietic differentiation of human pluripotent cells via mesodermal progenitors. PLoS ONE. 2011;6:e22261, doi:10.1371/journal.pone.0022261.
   PubMed Web of Science ®Google Scholar
• Pick M, Azzola L, Mossman A, et al. Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor 2 in hematopoiesis. Stem Cells. 2007;25:2206–2214, doi:10.1634/stemcells.2006-0713.
   PubMed Web of Science ®Google Scholar
• Zambidis ET, Peault B, Park TS, et al. Hematopoietic differentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages resembling human yolk sac development. Blood. 2005;106:860–870, doi:10.1182/blood-2004-11-4522.
   PubMed Web of Science ®Google Scholar
• Trivedi P, Hematti P. Simultaneous generation of CD34+ primitive hematopoietic cells and CD73+ mesenchymal stem cells from human embryonic stem cells cocultured with murine OP9 stromal cells. Exp Hematol. 2007;35:146–154, doi:10.1016/j.exphem.2006.09.003.
   PubMed Web of Science ®Google Scholar
• Wang L, Menendez P, Shojaei F, et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med. 2005;201:1603–1614, doi:10.1084/jem.20041888.
   PubMed Web of Science ®Google Scholar
• Narayan AD, Chase JL, Lewis RL, et al. Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients. Blood. 2006;107:2180–2183, doi:10.1182/blood-2005-05-1922.
   PubMed Web of Science ®Google Scholar
• Chicha L, Feki A, Boni A, et al. Human pluripotent stem cells differentiated in fully defined medium generate hematopoietic CD34− and CD34+ progenitors with distinct characteristics. PLoS ONE. 2011;6:e14733, doi:10.1371/journal.pone.0014733.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Mitra K, Koya M, et al. Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells. PLoS ONE. 2011;6:e25761, doi:10.1371/journal.pone.0025761.
   PubMed Web of Science ®Google Scholar
• Dias J, Gumenyuk M, Kang HJ, et al. Generation of red blood cells from human induced pluripotent stem cells. Stem Cells Dev. 2011;20:1639–1647, doi:10.1089/scd.2011.0078.
   PubMed Web of Science ®Google Scholar
• Dixon N, Kishnani PS, Zimmerman S. Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. Am J Med Genet Part C: Semin Med Genet. 2006;142C:149–157.
   PubMed Web of Science ®Google Scholar
• Blink M, van den Heuvel-Eibrink MM, de Haas V, et al. Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease. Haematologica. 2012;97:632–634, doi:10.3324/haematol.2011.057505.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in children with Down syndrome. Hematol Oncol Clin N. 2010;24:19–34, doi:10.1016/j.hoc.2009.11.009.
   PubMed Web of Science ®Google Scholar
• Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–152, doi:10.1038/ng955.
   PubMed Web of Science ®Google Scholar
• Alford KA, Reinhardt K, Garnett C, et al. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011;118:2222–2238, doi:10.1182/blood-2011-03-342774.
   PubMed Web of Science ®Google Scholar
• Klusmann JH, Godinho FJ, Heitmann K, et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Gene Dev. 2010;24:1659–1672, doi:10.1101/gad.1903410.
   PubMed Web of Science ®Google Scholar
• Li Z, Godinho FJ, Klusmann JH, et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613–619, doi:10.1038/ng1566.
   PubMed Web of Science ®Google Scholar
• Klusmann JH, Li Z, Bohmer K, et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 2010;24:478–490, doi:10.1101/gad.1856210.
   PubMed Web of Science ®Google Scholar
• Mou X, Wu Y, Cao H, et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down Syndrome. Stem Cell Res Ther. 2012;3:14.
   PubMed Web of Science ®Google Scholar
• De Vita S, Canzonetta C, Mulligan C, et al. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene. 2010;29:6102–6114, doi:10.1038/Onc.2010.351.
   PubMed Web of Science ®Google Scholar
• Chou ST, VanDorn D, Yao Y, et al. Patient-derived induced pluripotent stem cells reveal distinct hematopoietic defects conferred by Trisomy 21 and Truncated GATA-1. Blood. 2011;118: 416–416.
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe O, Roy A, Karadimitris A, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood. 2008;112:4507–4511, doi:10.1182/blood-2008-04-152967.
   PubMed Web of Science ®Google Scholar
• Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112:4503–4506, doi:10.1182/blood-2008-05-157859.
   PubMed Web of Science ®Google Scholar
• MacLean GA, Menne TF, Park IH, et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Blood. 2011;118:419–420.
   Web of Science ®Google Scholar
• Bedel A, Moreau-Gaudry F, Pasquet JM, et al. Induced pluripotent stem cells (iPSC) from chronic myeloid leukemia: study of BCR–ABL addiction and effect of tyrosine kinase inhibitors. Blood. 2011;118:1602–1603.
   Web of Science ®Google Scholar
• Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010;6:407–411, doi:10.1016/j.stem.2010.04.005.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Rieu P, Descamps-Latscha B, et al. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest. 2000;80:617–653.
   PubMed Web of Science ®Google Scholar
• Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191:677–691, doi:10.1083/jcb.201006052.
   PubMed Web of Science ®Google Scholar
• Bohn G, Welte K, Klein C. Severe congenital neutropenia: new genes explain an old disease. Curr Opin Rheumatol. 2007;19:644–650, doi:10.1097/BOR.0b013e3282f05cc2.
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107:4628–4635, doi:10.1182/blood-2005-11-4370.
   PubMed Web of Science ®Google Scholar
• Klein C, Grudzien M, Appaswamy G, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2007;39:86–92, doi:10.1038/ng1940.
   PubMed Web of Science ®Google Scholar
• Kostmann R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl. 1956;45:1–78.
   PubMedGoogle Scholar
• Modem S, Reddy TR. An anti-apoptotic protein, Hax-1, inhibits the HIV-1 rev function by altering its sub-cellular localization. J Cell Physiol. 2008;214:14–19, doi:10.1002/jcp.21305.
   PubMed Web of Science ®Google Scholar
• Grenda DS, Murakami M, Ghatak J, et al. Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis. Blood. 2007;110:4179–4187, doi:10.1182/blood-2006-11-057299.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Asai S, Komiya S, et al. A family of severe congenital neutropenia with −199C to A substitution in ELA2 promoter. Am J Hematol. 2006;81:985–986, doi:10.1002/ajh.20637.
   PubMed Web of Science ®Google Scholar
• Boxer LA, Stein S, Buckley D, et al. Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. J Pediatr. 2006;148:633–636, doi:10.1016/j.jpeds.2005.12.029.
   PubMed Web of Science ®Google Scholar
• Chao JR, Parganas E, Boyd K, et al. Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons. Nature. 2008;452:98–102, doi:10.1038/Nature06604.
   PubMed Web of Science ®Google Scholar
• Grenda DS, Johnson SE, Mayer JR, et al. Mice expressing a neutrophil elastase mutation derived from patients with severe congenital neutropenia have normal granulopoiesis. Blood. 2002;100:3221–3228, doi:10.1182/blood-2002-05-1372.
   PubMed Web of Science ®Google Scholar
• Hiramoto T, Ebihara Y, Mizoguchi Y, et al. Suppressed neutrophil development in hematopoiesis of induced pluripotent stem cells derived from a severe congenital neutropenia patient with ELA2 mutation. Blood. 2011;118:331.
   Web of Science ®Google Scholar
• Morishima T, Watanabe KI, Niwa A, et al. Reduced production of mature neutrophils from induced pluripotent stem cells derived from a severe congenital neutropenia patient with HAX1 gene deficiency. Blood. 2011;118:1033.
   Web of Science ®Google Scholar
• Gasparyan AY. Platelets in inflammation and thrombosis. Inflamm Allergy Drug Targets. 2010;9:319–321.
   PubMedGoogle Scholar
• Miyazaki H. Physiologic role of TPO in thrombopoiesis. Stem Cells. 1996;14(Suppl. 1):133–138, doi:10.1002/stem.5530140717.
   PubMedGoogle Scholar
• Geddis AE. Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer. 2011;57:199–203, doi:10.1002/pbc.22927.
   PubMed Web of Science ®Google Scholar
• Takayama N, Hirata S, Jono-Ohnishi R, et al. Modeling congenital amegakaryocytic thrombocytopenia using patient-specific induced pluripotent stem cells. Blood. 2011; 118:320–320.
   Web of Science ®Google Scholar
• Labbaye C, Spinello I, Quaranta MT, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol. 2008;10:788–801, doi:10.1038/Ncb1741.
   PubMed Web of Science ®Google Scholar
• Turner JI, Eisbacher M, Johnson LN, Chong B. Analysis of gene regulation by Fli-1 during megakaryopoeisis. Blood. 2003;102:158b–158b.
   Web of Science ®Google Scholar
• Preudhomme C, Renneville A, Bourdon V, et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood. 2009;113:5583–5587, doi:10.1182/blood-2008-07-168260.
   PubMed Web of Science ®Google Scholar
• Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364–1372.
   PubMed Web of Science ®Google Scholar
• Ardlie NG, Coupland WW, Schoefl GI. Hereditary thrombocytopathy: a familial bleeding disorder due to impaired platelet coagulant activity. Aust NZ J Med. 1976;6:37–45.
   PubMedGoogle Scholar
• Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia—a review. Br J Haematol. 2008;140:123–132, doi:10.1111/j.1365-2141.2007.06909.x.
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes—incidence and survival in the United States. Cancer. 2007;109:1536–1542, doi:10.1002/Cncr.22570.
   PubMed Web of Science ®Google Scholar
• Chen F, Peng GJ, Zhang K, et al. FANCA gene mutation analysis in Fanconi anemia patients. Zhonghua Xue Ye Xue Za Zhi. 2005;26:616–618.
   PubMedGoogle Scholar
• Song L. A possible approach for stem cell gene therapy of Fanconi anemia. Curr Gene Ther. 2009;9:26–32.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Berger R, Dutreix J. Bone marrow transplantation for Fanconi anemia. Semin Hematol. 1984;21:20–26.
   PubMed Web of Science ®Google Scholar
• Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009;460:53–59, doi:10.1038/nature08129.
   PubMed Web of Science ®Google Scholar
• Townes TM. Gene replacement therapy for sickle cell disease and other blood disorders. Hematol Am Soc Hematol Educ Prog. 2008;193–196, doi:10.1182/asheducation-2008.1.193.
   PubMedGoogle Scholar
• Sebastiano V, Maeder ML, Angstman JF, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells. 2011;29:1717–1726, doi:10.1002/stem.718.
   PubMed Web of Science ®Google Scholar
• Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood. 2011;118:4599–4608, doi:10.1182/blood-2011-02-335554.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng CG, Jiang Y, et al. Genetic correction of beta-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res. 2012;22:637–648, doi:10.1038/cr.2012.23.
   PubMed Web of Science ®Google Scholar
• Herbschleb-Voogt E, Pearson PL, Vossen JM, Meera Khan P. Basic defect in the expression of adenosine deaminase in ADA-SCID disease investigated through the cells of an obligate heterozygote. Hum Genet. 1981;56:379–386.
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther: J Am Soc Gene Ther. 2006;14:505–513, doi:10.1016/j.ymthe.2006.06.007.
   PubMed Web of Science ®Google Scholar
• Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413, doi:10.1126/science. 1070104.
   PubMed Web of Science ®Google Scholar
• Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877–886, doi:10.1016/j.cell.2008.07.041.
   PubMed Web of Science ®Google Scholar
• Dunbar CE. The yin and yang of stem cell gene therapy: insights into hematopoiesis, leukemogenesis, and gene therapy safety. Hematol Am Soc Hematol Educ Prog. 2007;2007:460–465, doi:10.1182/asheducation-2007.1.460.
   Google Scholar
• Gropp M, Itsykson P, Singer O, et al. Stable genetic modification of human embryonic stem cells by lentiviral vectors. Mol Ther: J Am Soc Gene Ther. 2003;7:281–287.
   PubMed Web of Science ®Google Scholar
• Ma Y, Ramezani A, Lewis R, et al. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells. 2003;21:111–117, doi:10.1634/stemcells.21-1-111.
   PubMed Web of Science ®Google Scholar
• Wu C, Dunbar CE. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Front Med. 2011;5:356–371, doi:10.1007/s11684-011-0159-1.
   PubMedGoogle Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419.
   PubMed Web of Science ®Google Scholar
• Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16:198–204, doi:10.1038/Nm.2088.
   PubMed Web of Science ®Google Scholar
• Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA. 1996;93:1156–1160.
   PubMed Web of Science ®Google Scholar
• Miller JC, Holmes MC, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. 2007;25:778–785, doi:10.1038/Nbt1319.
   PubMed Web of Science ®Google Scholar
• Doyon Y, Vo TD, Mendel MC, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. 2011;8:74–79, doi:10.1038/Nmeth.1539.
   PubMed Web of Science ®Google Scholar
• Zou J, Sweeney CL, Chou BK, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011;117:5561–5572, doi:10.1182/blood-2010-12-328161.
   PubMed Web of Science ®Google Scholar
• Muller LU, Milsom MD, Harris CE, et al. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 2012; doi:10.1182/blood-2012-02-408674.
   Web of Science ®Google Scholar
• Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood. 2009;114:3513–3523, doi:10.1182/blood-2009-03-191304.
   PubMed Web of Science ®Google Scholar
• Lapillonne H, Kobari L, Mazurier C, et al. Red blood cell generation from human induced pluripotent stem cells: perspectives for transfusion medicine. Haematologica. 2010;95:1651–1659, doi:10.3324/haematol.2010.023556.
   PubMed Web of Science ®Google Scholar
• Morishima T, Watanbe KI, Niwa A, et al. Neutrophil differentiation from human-induced pluripotent stem cells. J Cell Physiol. 2011;226:1283–1291, doi:10.1002/jcp.22456.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Takayama N, Nakauchi H, Eto K. Platelet production system using an immortalized megakaryocyte cell line derived from human pluripotent stem cells. Blood. 2011;118:3.
   Google Scholar
• Shafa M, Sjonnesen K, Yamashita A, et al. Expansion and long-term maintenance of induced pluripotent stem cells in stirred suspension bioreactors. J Tissue Eng Regen Med. 2012;6:462–472, doi:10.1002/term.450.
   PubMed Web of Science ®Google Scholar
• Olmer R, Lange A, Selzer S, et al. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng Part C: Methods. 2012; doi:10.1089/ten.TEC.2011.0717.
   PubMed Web of Science ®Google Scholar
• Zweigerdt R, Olmer R, Singh H, et al. Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc. 2011;6:689–700, doi:10.1038/nprot.2011.318.
   PubMed Web of Science ®Google Scholar
• Sachlos E, Risueno RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149:1284–1297, doi:10.1016/j.cell.2012.03.049.
   PubMed Web of Science ®Google Scholar
• Mou X, Wu Y, Cao H, et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down Syndrome. Stem Cell Res Ther. 2012;3:14, doi:10.1186/scrt105.
   PubMed Web of Science ®Google Scholar